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Introduction
Inflammatory breast cancer (IBC) is the most lethal form of
locally advanced breast cancer and accounts for approxi-
mately 6% of new breast cancer cases annually in the
United States [1,2]. IBC has distinct clinical and patholog-
ical features. Patients present with erythema, skin nodules,
dimpling of the skin (termed ‘peau d’orange’), all features
that develop rapidly, typically progressing within 6 months
[1–4]. One salient feature of IBC that is observed in tissue
sections is that cancer cells form emboli that spread
through the dermal lymphatics. The dermatotropism of
IBC is believed to be responsible for the clinical signs and
symptoms and probably enables effective dissemination to
distant sites [2]. These observations lead us to conclude
that IBC is highly invasive and that it is capable of metas-
tases from its inception. Indeed, at the time of diagnosis,
most patients have locoregional and/or distant metastatic
disease [3,4]. In spite of new advances in breast cancer
FBS = fetal bovine serum; GTPase = guanosine triphosphatase; HME = human mammary epithelial; IBC = inflammatory breast cancer; MTT = 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; PCR = polymerase chain reaction; RT–PCR = reverse transcriptase PCR; VEGF = vas-
cular endothelial growth factor; WISP3 = WNT-1 induced secreted protein 3.
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Abstract
Background: Inflammatory breast cancer (IBC) is the most
lethal form of locally advanced breast cancer. We found
concordant and consistent alterations of two genes in 90% of
IBC tumors when compared with stage-matched non-IBC
tumors: overexpression of RhoC guanosine triphosphatase and
loss of WNT-1 induced secreted protein 3 (WISP3). Further
work revealed that RhoC is a transforming oncogene for human
mammary epithelial (HME) cells. Despite the aggressiveness of
the RhoC-driven phenotype, it does not quantitatively reach
that of the true IBC tumors. We have demonstrated that
WISP3 has tumor growth and angiogenesis inhibitory functions
in IBC. We proposed that RhoC and WISP3 cooperate in the
development of IBC.
Methods: Using an antisense approach, we blocked WISP3
expression in HME cells. Cellular proliferation and growth were
determined using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide (MTT) assay and anchorage-independent
growth in a soft agar assay. Vascular endothelial growth factor
(VEGF) was measured in conditioned medium by enzyme-
linked immunosorbent assay.
Results: Antisense inhibition of WISP3 in HME cells increased
RhoC mRNA levels and resulted in an increase in cellular
proliferation, anchorage-independent growth and VEGF levels
in the conditioned medium. Conversely, restoration of WISP3
expression in the highly malignant IBC cell line SUM149 was
able to decrease the expression of RhoC protein.
Conclusion: WISP3 modulates RhoC expression in HME cells
and in the IBC cell line SUM149. This provides further
evidence that these two genes act in concert to give rise to the
highly aggressive IBC phenotype. We propose a model of this
interaction as a starting point for further investigations.
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therapy including multimodality approaches, the 5-year
disease-free survival rate is less than 45% [3,4].
Until recently, no biological markers defined the IBC phe-
notype. We proposed that a limited number of genetic
alterations, occurring in rapid succession or concordantly,
are responsible for the rapidly progressive and distinct
clinical and pathological features of IBC. Using a modified
version of the differential display technique and in situ
hybridization of human tumors, we identified two genes
that are consistently and concordantly altered in human
IBC when compared with stage-matched non-IBC tumors:
loss of WISP3 and overexpression of RhoC guanosine
triphosphatase (GTPase) [5].
WNT-1 induced secreted protein 3 (WISP3) is a member
of the CCN family of proteins, which have important bio-
logical functions in normal physiology as well as in car-
cinogenesis [6–8]. We found that WISP3 has growth and
angiogenesis inhibitory functions in IBC in vitro and in vivo
[9]. RhoC GTPase is a member of the Ras superfamily of
small GTPases. Activation of Rho proteins leads to assem-
bly of the actin–myosin contractile filaments into focal
adhesion complexes that bring about cell polarity and
facilitate motility [10–12]. Our laboratory has character-
ized RhoC as a transforming oncogene for human
mammary epithelial (HME) cells; its overexpression results
in a highly motile and invasive phenotype that recapitulates
the IBC phenotype. Predicated on the high rate of concor-
dance of RhoC and WISP3 changes in IBC, we propose
that these two genes cooperate to determine this highly
metastatic, unique breast cancer phenotype.
Materials and methods
Cell culture
The derivation of the SUM149 cell line has been
described previously by Ethier et al [13]. This cell line was
developed from a human primary IBC and has lost WISP3
expression [9]. HME cells were immortalized with human
papilloma virus E6/E7 and were characterized as being
keratin 19 positive, ensuring that they are from the same
differentiation lineage as the SUM149 IBC tumor cell line
[14,15]. MCF10A cells are spontaneously immortalized
human mammary epithelial cells. Cells were cultured in
Ham’s F-12 medium supplemented with 5% fetal bovine
serum (FBS), hydrocortisone (1 µg/ml), insulin (5 µg/ml),
fungizone (2.5 µg/ml), gentamycin (5 µg/ml), penicillin
(100 U/ml) and streptomycin (10 µg/ml) at 37°C under
10% CO2.
Construction of expression vectors and stable
transfections
Total RNAs were isolated from HME cells with a Trizol kit
(Life Technologies, Inc, Gaithersburg, MD). First-strand
cDNA synthesis was performed by using 1 µg of total
RNA with AMV reverse transcriptase (Promega, Madison,
WI) and oligo(dT) as a primer. A 2 µl portion of the reac-
tion mixture was used for amplification by polymerase
chain reaction (PCR). Human WISP3 cDNA was amplified
by PCR with the forward and reverse primers
5′-ACGAATTCAATGAACAAGCGGCG-3′ and 3′-GCG-
AATTCTTTTACAGAATCTTG-5′, respectively, under the
following conditions: denaturing for 1 min at 94°C, anneal-
ing for 1 min at 58°C, and elongation for 1 min at 72°C, for
35 cycles. PCR products were cloned into pGEM-T Easy
vector (Promega). The 1.1 kb full-length cDNA encoding
WISP3 was excised by EcoRI and subcloned into the
EcoRI site of pFlag-CMV4 vector (Sigma, St Louis, MO).
The insert was confirmed by DNA sequencing. The plas-
mids were purified. Subsequently, the SUM149 cells were
transfected with pFlag-WISP3 sense (SUM149/WISP3),
and HME cells were transfected with pFlag-WISP3 anti-
sense (HME/AS WISP3). MCF10A cells were stably tran-
fected with full-length RhoC cDNA (MCF10A/RhoC).
pFlag control vectors were used as controls (FuGene
TM 6 transfection reagent; Roch–Boehringer-Mannheim,
Germany). Transfectants were selected in the medium
containing 150 µg/ml G418. The cells surviving during
selection were expanded and maintained in the selected
medium.
Reverse transcriptase PCR (RT–PCR) analysis
Total RNA (1µg) from HME/AS WISP3 clones and empty
vector controls were reverse-transcribed with Superscript
reverse transcriptase (Invitrogen) using oligo(dT) and
random hexanucleotide primer for first-strand cDNA synthe-
sis. PCRs were performed directly on 1µl of first-strand
cDNA using 500nmol of each of the following gene-specific
primers: WISP3, 5′-ATGCAGGGGCTCCTCTTCTGC-3′
(forward primer) and 5′-ACTTTTCCCCCATTTGCTTG-3′
(reverse primer); RhoC , 5′-ATGGCTGCAATCCGAAAG-3′
(forward primer) and 5′-GATCTCAGAGAATGGGACAGC-3′
(reverse primer); GAPDH, 5′-CGGAGTCAACGGATTTG-
GTCGTAT-3′ (forward primer) and 5′-AGCCTTCTCCATG-
GTGGTGAAGAC-3′ (reverse primer). The 100µl reaction
volume consisted of 50mM KCl, 10mM Tris-HCl pH 8.3,
1.5mM MgCl2, and deoxynucleotide triphosphates (each at
200µM). PCR was performed for initial denaturation at 94°C
for 5 min, followed by 35 cycles of denaturation (94°C,
1 min), annealing (55°C, 1 min), and extension (72°C, 1 min)
with 5 units of Taq polymerase (Invitrogen). This was fol-
lowed by a final extension step at 72°C for 10 min. The prod-
ucts were analyzed on 1% agarose gels stained with
ethidium bromide and detected with ultraviolet illumination.
Western immunoblots
Western immunoblots were performed with polyclonal
anti-RhoC and anti-WISP3 antibodies. Cultured cells were
washed in ice-cold phosphate-buffered saline, lysed in
lysis buffer (10% glycerol, 50 mM Tris-HCl pH 7.4,
100 mM NaCl, 1% Nonidet P40, 2 mM MgCl2, 1 µg/ml
leupeptin, 1 µg/ml aprotinin, 1 mM phenylmethylsulphonyl
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fluoride) on ice for 5 min, and then centrifuged for 5 min at
4°C. Cleared lysates (each containing 50 µg of protein)
were subjected to SDS–polyacrylamide-gel electrophore-
sis and transferred to poly(vinylidene difluoride) mem-
brane. Western blots were performed as described
previously, with anti-RhoC rabbit polyclonal antibody and
anti-β-actin goat antibody (Sigma) at dilutions of 1 : 1500
and 1 : 2000, respectively [16].
Anchorage-independent growth
For studies of anchorage-independent growth we per-
formed soft agar assays on stable clones of HME/AS
WISP3, HME/Flag, and SUM149 cells. Each well of a six-
well plate was first layered with 0.6% agar diluted with
10% FBS-supplemented Ham’s F-12 medium complete
with growth factors. The cell layer was then prepared by
diluting agarose to concentrations of 0.3% and 0.6% with
103 cells in 2.5% FBS-supplemented Ham’s F-12/1.5
ml/well. Plates were maintained at 37°C under 10% CO2
for 3 weeks. Colonies 100 µm or more in diameter were
counted under the microscope with a grid.
Monolayer growth rate
Monolayer culture growth rate was determined by qualita-
tive measurement of the conversion of 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) to
a water-insoluble formazan by viable cells. In all, 3000
cells obtained for HME/AS WISP3 clones, HME/Flag, and
HME wild-type cells, suspended in 200 µl of culture
medium, were plated in 96-well plates and grown under
normal conditions. Cultures were assayed at 0, 2, 4, 6,
and 8 days by the addition of MTT and incubation for
1 hour at 37°C. The MTT-containing medium was aspi-
rated and 100 µl of dimethyl sulphoxide (Sigma) was
added to lyse the cells and solubilize the formazan.
Optical densities of the lysates were determined on a
Dynatech MR 5000 microplate reader at 595 nm.
Analysis of vascular endothelial growth factor
Conditioned medium was generated by incubating
HME/AS WISP3 cells, HME/Flag cells, and SUM149
cells in serum-free medium. After 3 days the medium was
collected, cleared of cell debris by centrifugation, concen-
trated approximately 10-fold through a Centriplus YM-10
column (Millipore, Bedford, MA). The levels of vascular
endothelial growth factor (VEGF), which is a factor known
to be secreted by IBC, were measured in the cell culture
supernatants by enzyme-linked immunosorbent assay, as
described previously [9,17].
Results
Inhibition of WISP3 increases RhoC mRNA levels in
immortalized HME cells and induces proliferation,
anchorage-independent growth, and VEGF production
To study the effects of inhibition of WISP3 expression on
the phenotype of HME cells, we established clones of
HME cells stably transfected with antisense WISP3 con-
structs (HME/AS WISP3). Effective inhibition of WISP3
expression was confirmed by RT–PCR (Fig. 1). Inhibition
of WISP3 expression in HME cells resulted in increased
expression of RhoC transcript in comparison with HME
cells transfected with the control empty vector (Fig. 1).
After 14 days of growth in soft agar, inhibition of WISP3
expression in HME cells resulted in a significant increase
in the number of colonies formed in comparison with the
empty vector control (t-test, P < 0.05 for both clones;
Fig. 2a). Inhibition of WISP3 expression resulted in an
increase in cellular proliferation (t-test, P < 0.05; Fig. 2b).
Previously, we had shown that restoration of WISP3
expression in an IBC cell line decreases the production of
VEGF, a major pro-angiogenic factor secreted by IBC [9].
To determine the effect of WISP3 inhibition on the secre-
tion of VEGF, we measured the concentration of VEGF in
the conditioned medium of the stably transfected HME/AS
WISP3 cells. Figure 2c shows that inhibition of WISP3
expression resulted in increased levels of VEGF in the
conditioned medium (t-test, P < 0.05 for all clones).
Restoration of WISP3 expression in SUM149 cells
decreases RhoC expression
Because decreased expression of WISP3 in HME cells
induced a significant increase in RhoC expression and
some features of RhoC induced functional changes
including anchorage-independent growth and production
of VEGF, we sought to determine whether restoration of
WISP3 expression in the SUM149 IBC cell line, which
has lost WISP3 expression in the wild type, has an effect
in RhoC expression. To test this, we stably transfected
WISP3 in SUM149 cells and measured RhoC expression
Figure 1
Inhibition of WISP3 in human mammary epithelial (HME) cells results in
an increase in RhoC transcript levels. Reverse transcriptase
polymerase chain reaction was conducted on vector and HME cells
that have inhibition of WISP3 expression using full-length WISP3
antisense mRNA. HME/AS WISP3 cells showed increased levels of
RhoC transcript in comparison with controls.
by Western blotting. Restoration of WISP3 expression in
SUM149 cells resulted in a decrease in RhoC protein
expression in comparison with the empty vector control
(Fig. 3). To investigate whether the relationship between
WISP3 and RhoC expression is reciprocal, we developed
MCF10A cells stably transfected with RhoC. These cells
showed a 2.5-fold decrease in WISP3 mRNA expression
(Fig. 4).
Discussion
Our previous work showed that the overexpression of
RhoC GTPase and the loss of WISP3 expression are
alterations that occur concordantly, more often in IBC than
in slow-growing locally advanced breast cancers. WISP3
loss was found in concert with RhoC GTPase overexpres-
sion in 90% of archival patient samples of IBC, but rarely
in stage-matched non-IBC tumors. Our laboratory further
demonstrated that RhoC GTPase is a transforming onco-
gene for HME cells and that WISP3 has tumor inhibitory
functions in IBC. However, neither alteration occurring in
isolation seems to be sufficient to develop the full-blown,
highly malignant IBC phenotype. Here we postulate that
dysregulation of WISP3 might upregulate RhoC GTPase
and thus enhance the aggressiveness of the phenotype
that results when these two alterations are present.
We have shown that overexpression of RhoC GTPase in
immortalized HME cells produced a striking tumorigenic
effect that, for the most part, recapitulates the phenotype
of the SUM149 IBC cell line. HME cells stably transfected
with RhoC exhibited greatly increased growth under
anchorage-independent conditions [15]. HME cells over-
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Figure 2
Inhibition of WISP3 induces anchorage-independent growth, proliferation and secretion of vascular endothelial growth factor (VEGF) in human
mammary epithelial (HME) cells. (a) Inhibition of WISP3 expression in HME cells. HME cells greatly increased the number of colonies formed in
soft agar in comparison with empty vector control (HME/Flag; t-test, P < 0.05 for both clones). (b) Effect of inhibition of WISP3 expression on the
proliferation of HME cells was studied with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The stable HME/AS
WISP3 cells have a significant increase in the proliferation rate in comparison with the empty vector control. Results are expressed as
means ± SEM of three independent experiments. In all, 3000 cells were assessed in each plate (t-test, P < 0.05). (c) Increase in VEGF measured
by enzyme-linked immunosorbent assay, as a result of inhibition of WISP3 expression in HME cells. Results are expressed as means ± SEM; t-test,
P < 0.05 for all clones.
Figure 3
Restoration of WISP3 expression in SUM149 inflammatory breast
cancer cells decreases RhoC protein expression. Western immunoblot
of cell culture of SUM 149 cells, empty vector control (SUM149/Flag),
and two WISP3-expressing clones with antibodies against RhoC and
actin. Gels were scanned and pixel intensity values were obtained.
Values for RhoC were corrected for loading by dividing the RhoC pixel
intensity by the actin pixel intensity.
Figure 4
RhoC overexpression in MCF10A cells results in a decrease in WISP3
mRNA level. Reverse transcriptase polymerase chain reaction was
conducted on vector and MCF10A cells stably overexpressing RhoC.
RhoC-overexpressing cells had decreased levels of WISP3 mRNA.
expressing RhoC produced up to 100-fold more colonies
than the controls, about 60% of the level of colony forma-
tion of the SUM149 IBC cell line. RhoC overexpression
induced motility and invasion in HME cells, and markedly
induced the production of angiogenic mediators including
VEGF [17]. The HME/RhoC transfectants formed tumors
when injected into the mammary fat pad of athymic nude
mice [15].
Importantly, restoration of WISP3 in SUM149 cells ame-
liorated these features of the malignant phenotype. The
SUM149/WISP3+ cells exhibited decreased growth in
vitro and in vivo in comparison with SUM149 cells trans-
fected with the empty vector. The invasiveness of
SUM149 cells was greatly decreased by restoring WISP3
expression. We also found that WISP3 markedly
decreased the concentration of angiogenic mediators in
the conditioned medium, especially VEGF, basic fibroblast
growth factor, and interleukin-6 [9]. Given the high speci-
ficity of WISP3 and RhoC alterations in IBC and their
interrelated functions in tumorigenesis, we propose that
they cooperate in the development of IBC.
Using an antisense approach, inhibition of WISP3
expression in HME cells resulted in a threefold increase
of RhoC GTPase transcript levels. The HME/AS WISP3
cells also exhibited increased cellular proliferation and
anchorage-independent growth in soft agar. The
HME/AS WISP3 cells produced significantly more
colonies in soft agar in comparison with the control
cells, an average of 58% of the level of colonies formed
by the SUM149 IBC cells. HME/AS WISP3 cells also
exhibited decreased production of VEGF in the condi-
tioned medium.
The relationship between RhoC and WISP3 expression
seems to be reciprocal. Restoration of WISP3 expression
in SUM149 cells, which have lost WISP3 in the wild-type
state, induced a 1.5-fold decrease in RhoC GTPase
expression. These results are intriguing because changes
in expression in Rho proteins by subtle factors such as
1.5–1.8 can be sufficient to modulate cellular behavior.
Overexpression of RhoC in spontaneously immortalized
HME cells, MCF10A, resulted in a 2.5-fold decrease in
WISP3 mRNA expression.
In summary, overexpression of RhoC GTPase and loss of
WISP3 are key genetic alterations in the development of
IBC, and they have complementary functions. RhoC
GTPase has a primary a role in motility, invasion, and
angiogenesis [15,17]. WISP3 has a pivotal role in tumor
growth, invasion, and angiogenesis [9]. Here we have
further strengthened the evidence that these genes coop-
erate in the development of IBC, because WISP3 expres-
sion modulates the expression of RhoC GTPase and its
functions.
Conclusion
IBC is the most lethal form of locally advanced breast
cancer, with a 5-year disease-free survival of less than
45%. Our work focused on determining the genetic alter-
ations that result in this aggressive breast cancer pheno-
type. Previously, we have found that RhoC and WISP3 are
consistently and concordantly altered in IBC tissues.
RhoC functions as an oncogene, and WISP3 as a tumor
suppressor gene. Here we provide evidence supporting
the hypothesis that these two genes act in concert to give
rise to the highly aggressive IBC phenotype. We propose
a model of this interaction as a starting point for further
investigations.
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